Exact Therapeutics As Stock Net Asset
| EXTX Stock | NOK 3.80 0.02 0.53% |
Exact Therapeutics AS fundamentals help investors to digest information that contributes to Exact Therapeutics' financial success or failures. It also enables traders to predict the movement of Exact Stock. The fundamental analysis module provides a way to measure Exact Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Exact Therapeutics stock.
Exact |
Exact Therapeutics AS Company Net Asset Analysis
Exact Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Exact Therapeutics Net Asset | 117.63 M |
Most of Exact Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Exact Therapeutics AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Exact Therapeutics AS has a Net Asset of 117.63 M. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The net asset for all Norway stocks is notably lower than that of the firm.
Exact Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Exact Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Exact Therapeutics could also be used in its relative valuation, which is a method of valuing Exact Therapeutics by comparing valuation metrics of similar companies.Exact Therapeutics is currently under evaluation in net asset category among its peers.
Exact Fundamentals
| Return On Equity | -0.46 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (844.98) % | |||
| Current Valuation | 432.68 M | |||
| Shares Outstanding | 30 M | |||
| Shares Owned By Insiders | 64.13 % | |||
| Shares Owned By Institutions | 26.24 % | |||
| Price To Book | 6.55 X | |||
| Price To Sales | 8,803 X | |||
| Gross Profit | 52 K | |||
| EBITDA | (56.66 M) | |||
| Net Income | (58.59 M) | |||
| Current Ratio | 15.66 X | |||
| Book Value Per Share | 2.60 X | |||
| Cash Flow From Operations | (55.11 M) | |||
| Earnings Per Share | (1.95) X | |||
| Beta | 0.21 | |||
| Market Capitalization | 359.97 M | |||
| Total Asset | 117.63 M | |||
| Net Asset | 117.63 M |
About Exact Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Exact Therapeutics AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exact Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exact Therapeutics AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Exact Stock
Exact Therapeutics financial ratios help investors to determine whether Exact Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Exact with respect to the benefits of owning Exact Therapeutics security.